FDA Approves Daraxonrasib, Landmark Drug for Pancreatic Cancer Treatment

The FDA's approval of daraxonrasib marks a significant milestone in the fight against pancreatic cancer, a disease with a grim prognosis. With the first effective oral treatment, patients can expect nearly double the median survival time, shifting the landscape of treatment options.